Back to Health

Who Should Avoid Ritonavir?

Who Should Avoid Ritonavir?
Bareback Guide 6 July 2026

Ritonavir is never chosen for its own sake. It is accepted as the cost of the drug it boosts, and where that cost is too high, the answer is usually a regimen needing no booster.

Who is excluded by contraindicated medicines?

Anyone taking simvastatin, lovastatin, midazolam, triazolam, ergot derivatives or certain antiarrhythmics. The list is long enough that checking is essential, and many entries have workable alternatives.

Who is excluded by enzyme inducers?

Anyone taking rifampicin, a strong enzyme-inducing anticonvulsant, or St John's wort. These defeat the boosting entirely, leaving the partner drug inadequate and risking resistance.

What about people using recreational drugs?

Not a prohibition and a serious safety consideration. Raised levels of stimulants and ketamine on boosted regimens have caused deaths. Being honest changes the prescription, and it is treated as clinical information.

What about people on inhaled steroids?

Worth reviewing rather than ruling out. Some inhaled and nasal steroids interact far less than fluticasone, and switching the inhaler is frequently easier than switching the HIV regimen.

What about people taking many other medicines?

The group for whom boosted regimens fit least well. Someone on several cardiac, respiratory or psychiatric medicines faces a cumulative interaction burden that an unboosted regimen simply avoids.

What about liver impairment?

Not recommended in severe hepatic impairment. Moderate impairment may be acceptable depending on the partner drug, which is a clinical judgement rather than a fixed rule.

What about tolerability?

Persistent nausea, diarrhoea or taste disturbance are legitimate reasons to switch. Cobicistat is generally better tolerated on these measures, and removing the booster entirely is better still where possible.

Is cobicistat a solution to the interactions?

Barely. Both block CYP3A4 potently and the affected drug list is essentially the same. Switching boosters improves comfort without solving the underlying problem, which is a common misunderstanding.

What about pregnancy?

An argument in ritonavir's favour rather than against. Where boosting is needed during pregnancy, ritonavir is generally preferred over cobicistat, because cobicistat-boosted levels fall more problematically in the later stages.

What about cardiovascular risk?

Worth weighing. Boosted regimens raise lipids over years, and for someone with substantial existing risk an unboosted integrase inhibitor may be preferable.

Is it ever unavoidable?

Occasionally. Where a boosted protease inhibitor is the only fully active option because of resistance, ritonavir comes with it. In that situation the interactions are managed rather than avoided.

What are the alternatives?

Cobicistat, the other booster, with a similar profile. Better, an unboosted regimen: integrase inhibitors such as dolutegravir and bictegravir need no booster at all, which removes the interaction problem entirely.

Why did unboosted regimens take over?

Largely because of this. Comparable effectiveness with a fraction of the interaction burden is a substantial practical advantage, and it is the reason boosting has become less common.

Can you switch away easily?

Usually. Moving from a boosted regimen to an unboosted integrase inhibitor is routine for people who are suppressed, and it typically simplifies everything else considerably.

What should you tell your clinic?

Everything you take including inhalers, over-the-counter products and recreational drugs. The interaction picture on a boosted regimen depends entirely on having a complete list.

Who decides?

You do, with a clinician. If the interaction burden is making your life difficult, that is a legitimate reason to ask for a change rather than something to absorb.